BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cobimetinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cobimetinib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06440850-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20261122
DTEND;VALUE=DATE:20261123
SUMMARY:Cobimetinib: Phase 2 readout est. (NCT06440850)
DESCRIPTION:Cobimetinib\, phase 2.\nStudy: Vemurafenib and Cobimetinib for 
 the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma 
 With BRAFV600E Mutation\nEstimated primary completion: 22 November 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cobimetinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06440850
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04302025-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Cobimetinib: Phase 2 readout est. (NCT04302025)
DESCRIPTION:Cobimetinib\, phase 2.\nStudy: A Study of Multiple Therapies in
  Biomarker-selected Participants With Resectable Stages IB-III Non-small C
 ell Lung Cancer (NSCLC)\nEstimated primary completion: 30 November 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cobimetinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04302025
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04835805-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cobimetinib: Phase 1 readout est. (NCT04835805)
DESCRIPTION:Cobimetinib\, phase 1\, Melanoma.\nStudy: A Study to Evaluate t
 he Safety and Activity of Belvarafenib as a Single Agent and in Combinatio
 n With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With N
 RAS-mutant Advanced Melanoma.\nEstimated primary completion: 31 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/cobimetinib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04835805
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03297606-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cobimetinib: Phase 2 readout est. (NCT03297606)
DESCRIPTION:Cobimetinib\, phase 2.\nStudy: Canadian Profiling and Targeted 
 Agent Utilization Trial (CAPTUR)\nEstimated primary completion: 31 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/cobimetinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03297
 606
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05691504-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Cobimetinib: Phase 1 readout est. (NCT05691504)
DESCRIPTION:Cobimetinib\, phase 1.\nStudy: Testing the Combination of APG-1
 252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Can
 cers\nEstimated primary completion: 1 February 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/cobimetinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05691504
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04005690-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Cobimetinib: Phase 1 readout est. (NCT04005690)
DESCRIPTION:Cobimetinib\, phase 1.\nStudy: Targeted Pathway Inhibition in P
 atients With Pancreatic Cancer\nEstimated primary completion: 1 June 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/cobimetinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04005690
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Cobimetinib: Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Cobimetinib\, phase 2/3.\nStudy: A Study to Evaluate the Effica
 cy and Safety of Multiple Targeted Therapies as Treatments for Participant
 s With Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 3
 0 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cobimeti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03178552
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03181100-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Cobimetinib: Phase 2 readout est. (NCT03181100)
DESCRIPTION:Cobimetinib\, phase 2.\nStudy: Atezolizumab With Chemotherapy i
 n Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cance
 r\nEstimated primary completion: 31 July 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/cobimetinib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03181100
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Cobimetinib: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Cobimetinib\, phase 2.\nStudy: The Drug Rediscovery Protocol (D
 RUP Trial)\nEstimated primary completion: September 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/cobimetinib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02693535-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cobimetinib: Phase 2 readout est. (NCT02693535)
DESCRIPTION:Cobimetinib\, phase 2.\nStudy: TAPUR: Testing the Use of Food a
 nd Drug Administration (FDA) Approved Drugs That Target a Specific Abnorma
 lity in a Tumor Gene in People With Advanced Stage Cancer\nEstimated prima
 ry completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/cobimetinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT02693535
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03202316-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cobimetinib: Phase 2 readout est. (NCT03202316)
DESCRIPTION:Cobimetinib\, phase 2.\nStudy: Atezolizumab\, Cobimetinib\, and
  Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Infl
 ammatory Breast Cancer\nEstimated primary completion: 31 December 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/cobimetinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03202316
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04079179-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Cobimetinib: Phase 2 readout est. (NCT04079179)
DESCRIPTION:Cobimetinib\, phase 2.\nStudy: Cobimetinib in Refractory Langer
 hans Cell Histiocytosis (LCH)\, and Other Histiocytic Disorders\nEstimated
  primary completion: January 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/cobimetinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04079179
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06813079-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20280217
DTEND;VALUE=DATE:20280218
SUMMARY:Cobimetinib: Phase 2 readout est. (NCT06813079)
DESCRIPTION:Cobimetinib\, phase 2.\nStudy: Using Tumor Models to Determine 
 Treatments\nEstimated primary completion: 17 February 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/cobimetinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06813079
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04931342-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Cobimetinib: Phase 2 readout est. (NCT04931342)
DESCRIPTION:Cobimetinib\, phase 2.\nStudy: A Study Evaluating the Efficacy 
 and Safety of Biomarker-Driven Therapies in Patients With Persistent or Re
 current Rare Epithelial Ovarian Tumors\nEstimated primary completion: 28 F
 ebruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cobimet
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04931342
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03175432-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Cobimetinib: Phase 2 readout est. (NCT03175432)
DESCRIPTION:Cobimetinib\, phase 2\, Melanoma.\nStudy: Bevacizumab and Atezo
 lizumab With or Without Cobimetinib in Treating Patients With Untreated Me
 lanoma Brain Metastases\nEstimated primary completion: 30 June 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/cobimetinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT03175432
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03768063-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20280705
DTEND;VALUE=DATE:20280706
SUMMARY:Cobimetinib: Phase 3 readout est. (NCT03768063)
DESCRIPTION:Cobimetinib\, phase 3.\nStudy: A Study in Patients Previously E
 nrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizu
 mab Study\nEstimated primary completion: 5 July 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/cobimetinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03768063
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03202940-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Cobimetinib: Phase 1/2 readout est. (NCT03202940)
DESCRIPTION:Cobimetinib\, phase 1/2.\nStudy: A Phase IB/II Study of Alectin
 ib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC\nEsti
 mated primary completion: 1 January 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/cobimetinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03202940
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04341181-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Cobimetinib: Phase 2 readout est. (NCT04341181)
DESCRIPTION:Cobimetinib\, phase 2.\nStudy: ProTarget - A Danish Nationwide 
 Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling\nEs
 timated primary completion: 30 April 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/cobimetinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04341181
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07449754-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Cobimetinib: Phase 2 readout est. (NCT07449754)
DESCRIPTION:Cobimetinib\, phase 2\, Melanoma.\nStudy: Belvarafenib in Combi
 nation With Cobimetinib in Patients With Locally Advanced or Metastatic NR
 AS-Mutant Melanoma\nEstimated primary completion: September 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/cobimetinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07449754
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768178-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Cobimetinib: Phase 2/3 readout est. (NCT05768178)
DESCRIPTION:Cobimetinib\, phase 2/3\, Melanoma.\nStudy: DETERMINE Trial Tre
 atment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patien
 ts With BRAF Positive Cancers.\nEstimated primary completion: October 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/cobimetinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05768178
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05722886-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Cobimetinib: Phase 2/3 readout est. (NCT05722886)
DESCRIPTION:Cobimetinib\, phase 2/3.\nStudy: DETERMINE (Determining Extende
 d Therapeutic Indications for Existing Drugs in Rare Molecularly Defined I
 ndications Using a National Evaluation Platform Trial) - Master Screening 
 Protocol\nEstimated primary completion: October 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/cobimetinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05722886
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05159245-2167@assetmemo.bio
DTSTAMP:20261121T004112Z
DTSTART;VALUE=DATE:20311125
DTEND;VALUE=DATE:20311126
SUMMARY:Cobimetinib: Phase 2 readout est. (NCT05159245)
DESCRIPTION:Cobimetinib\, phase 2.\nStudy: The Finnish National Study to Fa
 cilitate Patient Access to Targeted Anti-cancer Drugs\nEstimated primary c
 ompletion: 25 November 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/cobimetinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05159245
URL:https://assetmemo.bio/drug/cobimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
